Detalles de la búsqueda
1.
Osimertinib with or without Chemotherapy in EGFR-Mutated Advanced NSCLC.
N Engl J Med
; 389(21): 1935-1948, 2023 Nov 23.
Artículo
en Inglés
| MEDLINE | ID: mdl-37937763
2.
Quality of life with cemiplimab plus chemotherapy for first-line treatment of advanced non-small cell lung cancer: Patient-reported outcomes from phase 3 EMPOWER-Lung 3.
Cancer
; 129(14): 2256-2265, 2023 07 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-37151113
3.
Osimertinib in Resected EGFR-Mutated Non-Small-Cell Lung Cancer.
N Engl J Med
; 383(18): 1711-1723, 2020 10 29.
Artículo
en Inglés
| MEDLINE | ID: mdl-32955177
4.
Patterns of Care and Barriers to Utilization of Definitive Concurrent Chemoradiation Therapy for Stage III Non-Small Cell Lung Cancer in Russia.
J Cancer Educ
; 37(5): 1378-1384, 2022 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-33533013
5.
A plain language summary of results from the ADAURA study: osimertinib after surgery for patients who have early-stage EGFR-mutated non-small cell lung cancer.
Future Oncol
; 17(35): 4827-4835, 2021 Dec 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-34723634
6.
Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial.
Lancet
; 393(10183): 1819-1830, 2019 05 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-30955977
7.
Towards standardization of next-generation sequencing of FFPE samples for clinical oncology: intrinsic obstacles and possible solutions.
J Transl Med
; 15(1): 22, 2017 01 31.
Artículo
en Inglés
| MEDLINE | ID: mdl-28137276
8.
Simultaneous expression of flotillin-1, flotillin-2, stomatin and caveolin-1 in non-small cell lung cancer and soft tissue sarcomas.
BMC Cancer
; 14: 100, 2014 Feb 17.
Artículo
en Inglés
| MEDLINE | ID: mdl-24533441
9.
Cemiplimab plus chemotherapy versus chemotherapy alone in non-small cell lung cancer with PD-L1 ≥ 1 %: A subgroup analysis from the EMPOWER-Lung 3 part 2 trial.
Lung Cancer
; 193: 107821, 2024 May 13.
Artículo
en Inglés
| MEDLINE | ID: mdl-38820979
10.
CNS Efficacy of Osimertinib With or Without Chemotherapy in Epidermal Growth Factor Receptor-Mutated Advanced Non-Small-Cell Lung Cancer.
J Clin Oncol
; 42(7): 808-820, 2024 Mar 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-38042525
11.
Five-Year Outcomes With Pembrolizumab Versus Chemotherapy as First-Line Therapy in Patients With Non-Small-Cell Lung Cancer and Programmed Death Ligand-1 Tumor Proportion Score ≥ 1% in the KEYNOTE-042 Study.
J Clin Oncol
; 41(11): 1986-1991, 2023 04 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-36306479
12.
Durvalumab With or Without Tremelimumab in Combination With Chemotherapy as First-Line Therapy for Metastatic Non-Small-Cell Lung Cancer: The Phase III POSEIDON Study.
J Clin Oncol
; 41(6): 1213-1227, 2023 02 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-36327426
13.
Cemiplimab Plus Chemotherapy Versus Chemotherapy Alone in Advanced NSCLC: 2-Year Follow-Up From the Phase 3 EMPOWER-Lung 3 Part 2 Trial.
J Thorac Oncol
; 18(6): 755-768, 2023 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-37001859
14.
Adjuvant Osimertinib for Resected EGFR-Mutated Stage IB-IIIA Non-Small-Cell Lung Cancer: Updated Results From the Phase III Randomized ADAURA Trial.
J Clin Oncol
; 41(10): 1830-1840, 2023 04 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-36720083
15.
Health-Related Quality of Life Outcomes in Patients with Resected Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer Who Received Adjuvant Osimertinib in the Phase III ADAURA Trial.
Clin Cancer Res
; 28(11): 2286-2296, 2022 06 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-35012927
16.
Postoperative Chemotherapy Use and Outcomes From ADAURA: Osimertinib as Adjuvant Therapy for Resected EGFR-Mutated NSCLC.
J Thorac Oncol
; 17(3): 423-433, 2022 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-34740861
17.
Cemiplimab plus chemotherapy versus chemotherapy alone in non-small cell lung cancer: a randomized, controlled, double-blind phase 3 trial.
Nat Med
; 28(11): 2374-2380, 2022 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-36008722
18.
Afatinib in EGFR TKI-naïve patients with locally advanced or metastatic EGFR mutation-positive non-small cell lung cancer: Interim analysis of a Phase 3b study.
Lung Cancer
; 152: 127-134, 2021 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-33387727
19.
Afatinib in EGFR TKI-Naïve Patients with Locally Advanced or Metastatic EGFR Mutation-Positive Non-Small Cell Lung Cancer: A Pooled Analysis of Three Phase IIIb Studies.
Front Oncol
; 11: 709877, 2021.
Artículo
en Inglés
| MEDLINE | ID: mdl-34307179
20.
Rovalpituzumab Tesirine as a Maintenance Therapy After First-Line Platinum-Based Chemotherapy in Patients With Extensive-Stage-SCLC: Results From the Phase 3 MERU Study.
J Thorac Oncol
; 16(9): 1570-1581, 2021 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-33823285